|
||||||
|
 | |
| |
| |
| |
| |
| |
| |
| |
| |
| |
| |
| |
| |
|
Gene: ENSG00000115507 |
Summary for OTX1 |
 Gene summary |
| Gene information | Ensembl ID | ENSG00000115507 | Gene symbol | OTX1 |
| Gene name | orthodenticle homeobox 1 | |
| HGNC | 8521 | |
| Entrez ID | 5013 | |
| Gene type | protein_coding | |
| Synonyms | OTX1| | |
| UniProtAcc | P32242 |
| Drugs associated with this gene(DrugBank). |
| Gene ID | Gene Symbol | Drug ID | Drug Name | Drug Type |
| Cancer therapeutic drugs associated with this gene(NCI). |
| Gene ID | Gene Name | Drug ID | Drug Name | Drug Type | Cancer |
Top |
Structure and expression level for OTX1 |
| AS events and RNA A-to-I editing events of the gene in TCGA based on Genvode V22 structure. ∗For more information on exon skipping events please check the ExonskipDB database. ∗For more information on exon skipping events please check the CAeditome database. |
 |
| Landscape of gene expressions across multiple cancer types. |
 |
| Differentially expressed gene analysis between tumor male and tumor female samples. |
| Coding Name | Base Mean | log2FoldChange | lfcSE | Stat | P value | P.adjust Value | Cancer Type |
| Differentially expressed gene analysis between tumor male and normal male samples. |
 |
| Coding Name | Base Mean | log2FoldChange | lfcSE | Stat | P value | P.adjust Value | Cancer Type |
| OTX1 | 8.70e+02 | 1.40e+00 | 4.14e-01 | 3.39e+00 | 7.04e-04 | 4.80e-03 | ESCA |
| Differentially expressed gene analysis between tumor female and normal female samples. |
| Coding Name | Base Mean | log2FoldChange | lfcSE | Stat | P value | P.adjust Value | Cancer Type |
Top |
Sex-biased somatic mutation for OTX1 |
| ∗For more information on exon skipping events please check the ExonskipDB database. |
| Gene ID | Cancer Type | Hugo Symbol | Male | Female | pval | or | ci.up | ci.low | adjPval |
Top |
DNA methylation with beta values for OTX1 |
| Landscape of DNA methylation across multiple cancer types. |
 |
| Differentially expressed CpG sites between male tumor and female tumor patients. |
| Cancer Type | CpG Site | Position | CpG Island | Position to Gene | ave1 | ave2 | wilcoxon.w | wilcoxon.p | padj | dBeta |
| BRCA | cg18126442 | chr2:63048733 | CGI:chr2:63047340-63052295 | promoter | 5.67e-01 | 7.09e-01 | -2.64e+00 | 8.25e-03 | 2.48e-02 | -1.41e-01 |
| BRCA | cg00445126 | chr2:63048875 | CGI:chr2:63047340-63052295 | promoter | 5.31e-01 | 6.73e-01 | -2.39e+00 | 1.69e-02 | 3.28e-02 | -1.41e-01 |
| BRCA | cg06192497 | chr2:63049081 | CGI:chr2:63047340-63052295 | promoter | 5.27e-01 | 7.44e-01 | -2.57e+00 | 1.02e-02 | 2.68e-02 | -2.17e-01 |
| BRCA | cg22197050 | chr2:63049048 | CGI:chr2:63047340-63052295 | promoter | 5.63e-01 | 7.10e-01 | -2.07e+00 | 3.82e-02 | 4.51e-02 | -1.47e-01 |
| BRCA | cg02606403 | chr2:63049133 | CGI:chr2:63047340-63052295 | promoter | 4.55e-01 | 6.28e-01 | -2.47e+00 | 1.36e-02 | 3.00e-02 | -1.73e-01 |
| SARC | cg18126442 | chr2:63048733 | CGI:chr2:63047340-63052295 | promoter | 5.70e-01 | 4.45e-01 | 4.05e+00 | 5.15e-05 | 2.84e-04 | 1.25e-01 |
| SARC | cg00445126 | chr2:63048875 | CGI:chr2:63047340-63052295 | promoter | 4.92e-01 | 3.85e-01 | 3.23e+00 | 1.25e-03 | 4.14e-03 | 1.07e-01 |
| UVM | cg01940425 | chr2:63049430 | CGI:chr2:63047340-63052295 | promoter | 1.03e-01 | 2.09e-01 | -2.57e+00 | 1.03e-02 | 2.21e-02 | -1.06e-01 |
| Differentially expressed CpG sites between male tumor and male normal patients. |
| Cancer Type | CpG Site | Position | CpG Island | Position to Gene | ave1 | ave2 | wilcoxon.w | wilcoxon.p | padj | dBeta |
| KIRC | cg06192497 | chr2:63049081 | CGI:chr2:63047340-63052295 | promoter | 2.79e-01 | 1.26e-01 | 3.14e+00 | 1.71e-03 | 2.50e-03 | 1.53e-01 |
| KIRC | cg01940425 | chr2:63049430 | CGI:chr2:63047340-63052295 | promoter | 2.85e-01 | 1.52e-01 | 2.82e+00 | 4.76e-03 | 6.18e-03 | 1.33e-01 |
| THCA | cg18126442 | chr2:63048733 | CGI:chr2:63047340-63052295 | promoter | 3.19e-01 | 1.95e-01 | 3.29e+00 | 1.00e-03 | 3.13e-03 | 1.23e-01 |
| THCA | cg00445126 | chr2:63048875 | CGI:chr2:63047340-63052295 | promoter | 3.20e-01 | 2.08e-01 | 2.37e+00 | 1.80e-02 | 2.50e-02 | 1.11e-01 |
| THCA | cg06192497 | chr2:63049081 | CGI:chr2:63047340-63052295 | promoter | 1.52e-01 | 3.75e-02 | 4.02e+00 | 5.86e-05 | 4.11e-04 | 1.15e-01 |
| THCA | cg03957108 | chr2:63049410 | CGI:chr2:63047340-63052295 | promoter | 3.00e-01 | 1.56e-01 | 4.25e+00 | 2.12e-05 | 2.05e-04 | 1.43e-01 |
| THCA | cg10658666 | chr2:63049583 | CGI:chr2:63047340-63052295 | promoter | 3.72e-01 | 2.40e-01 | 3.64e+00 | 2.74e-04 | 1.23e-03 | 1.32e-01 |
| LUSC | cg14174204 | chr2:63049565 | CGI:chr2:63047340-63052295 | promoter | 1.43e-01 | 2.46e-01 | -4.18e+00 | 2.88e-05 | 5.26e-04 | -1.03e-01 |
| LUSC | cg10658666 | chr2:63049583 | CGI:chr2:63047340-63052295 | promoter | 1.72e-01 | 3.00e-01 | -4.16e+00 | 3.19e-05 | 5.26e-04 | -1.28e-01 |
| LUSC | cg08210688 | chr2:63049588 | CGI:chr2:63047340-63052295 | promoter | 1.30e-01 | 2.40e-01 | -4.05e+00 | 5.21e-05 | 5.63e-04 | -1.10e-01 |
| LUSC | cg10487970 | chr2:63049895 | CGI:chr2:63047340-63052295 | promoter | 1.43e-01 | 2.45e-01 | -4.24e+00 | 2.20e-05 | 5.26e-04 | -1.02e-01 |
| BLCA | cg08210688 | chr2:63049588 | CGI:chr2:63047340-63052295 | promoter | 1.53e-01 | 2.58e-01 | -3.88e+00 | 1.03e-04 | 4.08e-04 | -1.05e-01 |
| LIHC | cg14174204 | chr2:63049565 | CGI:chr2:63047340-63052295 | promoter | 1.67e-01 | 2.79e-01 | -5.26e+00 | 1.45e-07 | 7.17e-07 | -1.11e-01 |
| CHOL | cg18126442 | chr2:63048733 | CGI:chr2:63047340-63052295 | promoter | 5.37e-01 | 2.84e-01 | 2.65e+00 | 7.96e-03 | 1.92e-02 | 2.53e-01 |
| CHOL | cg00445126 | chr2:63048875 | CGI:chr2:63047340-63052295 | promoter | 4.98e-01 | 2.68e-01 | 2.43e+00 | 1.50e-02 | 2.65e-02 | 2.30e-01 |
| CHOL | cg06192497 | chr2:63049081 | CGI:chr2:63047340-63052295 | promoter | 5.71e-01 | 1.46e-01 | 2.36e+00 | 1.83e-02 | 2.92e-02 | 4.25e-01 |
| CHOL | cg13433250 | chr2:63048819 | CGI:chr2:63047340-63052295 | promoter | 5.56e-01 | 3.53e-01 | 2.65e+00 | 7.96e-03 | 1.92e-02 | 2.04e-01 |
| CHOL | cg22197050 | chr2:63049048 | CGI:chr2:63047340-63052295 | promoter | 4.97e-01 | 3.18e-01 | 2.14e+00 | 3.25e-02 | 3.87e-02 | 1.79e-01 |
| CHOL | cg02606403 | chr2:63049133 | CGI:chr2:63047340-63052295 | promoter | 4.48e-01 | 2.18e-01 | 2.21e+00 | 2.70e-02 | 3.50e-02 | 2.31e-01 |
| Differentially expressed CpG sites between female tumor and female normal patients. |
| Cancer Type | CpG Site | Position | CpG Island | Position to Gene | ave1 | ave2 | wilcoxon.w | wilcoxon.p | padj | dBeta |
| BRCA | cg18126442 | chr2:63048733 | CGI:chr2:63047340-63052295 | promoter | 5.67e-01 | 4.47e-01 | 7.32e+00 | 2.54e-13 | 8.17e-13 | 1.21e-01 |
| BRCA | cg00445126 | chr2:63048875 | CGI:chr2:63047340-63052295 | promoter | 5.31e-01 | 3.81e-01 | 8.51e+00 | 1.74e-17 | 7.68e-17 | 1.50e-01 |
| BRCA | cg06192497 | chr2:63049081 | CGI:chr2:63047340-63052295 | promoter | 5.27e-01 | 2.82e-01 | 8.26e+00 | 1.51e-16 | 6.19e-16 | 2.45e-01 |
| BRCA | cg01940425 | chr2:63049430 | CGI:chr2:63047340-63052295 | promoter | 3.41e-01 | 1.39e-01 | 5.76e+00 | 8.57e-09 | 1.93e-08 | 2.02e-01 |
| BRCA | cg15862215 | chr2:63049875 | CGI:chr2:63047340-63052295 | promoter | 2.43e-01 | 9.64e-02 | 2.12e+00 | 3.41e-02 | 3.51e-02 | 1.47e-01 |
| BRCA | cg13433250 | chr2:63048819 | CGI:chr2:63047340-63052295 | promoter | 5.27e-01 | 3.91e-01 | 8.94e+00 | 3.87e-19 | 1.95e-18 | 1.36e-01 |
| BRCA | cg22197050 | chr2:63049048 | CGI:chr2:63047340-63052295 | promoter | 5.63e-01 | 3.90e-01 | 8.90e+00 | 5.54e-19 | 2.75e-18 | 1.73e-01 |
| BRCA | cg02606403 | chr2:63049133 | CGI:chr2:63047340-63052295 | promoter | 4.55e-01 | 2.33e-01 | 9.97e+00 | 2.13e-23 | 1.55e-22 | 2.22e-01 |
| BRCA | cg03957108 | chr2:63049410 | CGI:chr2:63047340-63052295 | promoter | 4.16e-01 | 2.53e-01 | 5.31e+00 | 1.09e-07 | 2.22e-07 | 1.64e-01 |
| THCA | cg13471114 | chr2:63049849 | CGI:chr2:63047340-63052295 | promoter | 2.17e-01 | 1.11e-01 | 2.21e+00 | 2.68e-02 | 3.10e-02 | 1.06e-01 |
| HNSC | cg18126442 | chr2:63048733 | CGI:chr2:63047340-63052295 | promoter | 2.85e-01 | 1.37e-01 | 2.45e+00 | 1.41e-02 | 2.25e-02 | 1.49e-01 |
| HNSC | cg00445126 | chr2:63048875 | CGI:chr2:63047340-63052295 | promoter | 2.21e-01 | 1.01e-01 | 2.15e+00 | 3.16e-02 | 3.67e-02 | 1.19e-01 |
| HNSC | cg00431699 | chr2:63051696 | CGI:chr2:63047340-63052295 | promoter,exon,gene body | 4.04e-01 | 2.16e-01 | 2.78e+00 | 5.40e-03 | 1.38e-02 | 1.88e-01 |
| BLCA | cg00431699 | chr2:63051696 | CGI:chr2:63047340-63052295 | promoter,exon,gene body | 4.38e-01 | 2.72e-01 | 2.69e+00 | 7.17e-03 | 1.42e-02 | 1.66e-01 |
| KIRP | cg15862215 | chr2:63049875 | CGI:chr2:63047340-63052295 | promoter | 2.01e-01 | 8.84e-02 | 2.42e+00 | 1.54e-02 | 2.25e-02 | 1.13e-01 |
| KIRP | cg22197050 | chr2:63049048 | CGI:chr2:63047340-63052295 | promoter | 4.54e-01 | 3.23e-01 | 2.26e+00 | 2.36e-02 | 2.99e-02 | 1.31e-01 |
Top |
Exon skipping events with PSI in TCGA for OTX1 |
| ∗Please access ExonSkipDB for exon skipping annotation. |
| Differentially expressed exon skipping events between male tumor and female tumor patients. |
| Cancer Type | Exon Skipping | ave.female_T | ave.female_N | wilcoxon.w | wilcoxon.p | padj | dPSI |
| Differentially expressed exon skipping events between male tumor and male normal patients. |
| Cancer Type | Exon Skipping | ave.female_T | ave.female_N | wilcoxon.w | wilcoxon.p | padj | dPSI |
| Differentially expressed exon skipping events between female tumor and female normal patients. |
| Cancer Type | Exon Skipping | ave.female_T | ave.female_N | wilcoxon.w | wilcoxon.p | padj | dPSI |
Top |
RNA A-to-I editing events in TCGA for OTX1 |
| ∗Please access CAeditome for RNA editing annotation. |
| Differentially expressed RNA editing events between male tumor and female tumor patients. |
| Cancer Type | Transcript | Editing | ave.male_T | ave.female_T | wilcoxon.w | wilcoxon.p | p_adj | dFre |
| Differentially expressed RNA editing events between male tumor and male normal patients. |
| Cancer Type | Transcript | Editing | ave.male_T | ave.female_T | wilcoxon.w | wilcoxon.p | p_adj | dFre |
| Differentially expressed RNA editing events between female tumor and female normal patients. |
| Cancer Type | Transcript | Editing | ave.male_T | ave.female_T | wilcoxon.w | wilcoxon.p | p_adj | dFre |
| Protein coding RNA editing(s). |
| Editing Position | Variant Type | Gene Symbol | Transcript ID | NTchange | AAchange |
Top |
Sex-biased TF-Gene network for OTX1 |
| TFs related to OTX1. ∗The female-biased TF-gene edges were identified if Female_Edge_threshold>0.98 and Male_Edge_threshold<=0.98. ∗The male-biased TF-gene edges were identified if Male_Edge_threshold>0.98 and Female_Edge_threshold<=0.98. |
| Cancer Type | TF | Target Gene | Male Edge Score | Male Edge Threshold | Female Edge Score | Female Edge Threshold | Type |
| OTX1 related gene. ∗Only the gene encode TF might with this result. ∗For more information please check Sex-biased TF-Coding gene network. |
 |
Top |
Sex-biased RBP-ES network for OTX1 |
| RBPs related to ES in OTX1. ∗The female-biased RBP-ES edges were identified if Female_Edge_threshold>0.98 and Male_Edge_threshold<=0.98. ∗The male-biased RBP-ES edges were identified if Male_Edge_threshold>0.98 and Female_Edge_threshold<=0.98. |
| Cancer Type | RBP | Target ES | Male Edge Score | Male Edge Threshold | Female Edge Score | Female Edge Threshold | Type |
| OTX1 related ES. ∗Only the gene encode RBP might with this result. ∗For more information please check Sex-biased RBP-ES network in cancer. |
Top |
Sex-biased CeRNA regulation of gene |
| Sex-biased CeRNA regulation of gene. |
| Gene ID | ceRNA(lncRNA-miRNA-mRNA) | Group | Cancer Type |
| ENSG00000115507 | AL359853.1,hsa-mir-195,OTX1 | Female-specific ceRNA | TCGA-THCA |
Top |
Sex-biased eQTL regulation of gene |
| Sex-biased eQTL regulation of gene (The figures only show the pairs with FDR <1e-5. For more information please check the below table). |
| eQTL | Description |
| Male-specific eQTL regulation. |
| SNP ID | SNP Info | Position to Gene | Effect Score | FDR | Cancer Type | Biased Type |
| rs72884996 | chr2:61241626:T:C | - | 0.239053526281851 | 0.000257932315660744 | GBM | Female-baised eQTL |
| rs76426372 | chr2:61315314:C:T | - | 0.231573219137206 | 0.00244167536451808 | GBM | Female-baised eQTL |
| rs72884995 | chr2:61236974:T:C | - | 0.218305327747007 | 0.00594438575194096 | GBM | Female-baised eQTL |
| rs9967730 | chr2:61286719:G:T | - | 0.218305327747007 | 0.00594438575194096 | GBM | Female-baised eQTL |
| rs72886814 | chr2:61287287:G:A | - | 0.218305327747007 | 0.00594438575194096 | GBM | Female-baised eQTL |
| rs2067549 | chr2:61288270:G:C | - | 0.218305327747007 | 0.00594438575194096 | GBM | Female-baised eQTL |
| rs2067548 | chr2:61288446:A:G | - | 0.218305327747007 | 0.00594438575194096 | GBM | Female-baised eQTL |
| rs112834063 | chr2:61294497:C:A | - | 0.218305327747007 | 0.00594438575194096 | GBM | Female-baised eQTL |
| rs11889702 | chr2:61297247:C:T | - | 0.218305327747007 | 0.00594438575194096 | GBM | Female-baised eQTL |
| rs72886828 | chr2:61297984:C:T | - | 0.218305327747007 | 0.00594438575194096 | GBM | Female-baised eQTL |
| rs113655904 | chr2:61482057:T:C | - | 0.218305327747007 | 0.00594438575194096 | GBM | Female-baised eQTL |
| rs76353526 | chr2:61891379:G:A | - | 0.227213915223417 | 0.00801004967871792 | GBM | Female-baised eQTL |
| rs901532 | chr2:62536212:C:T | - | 0.204177408911086 | 0.0130313504955844 | GBM | Female-baised eQTL |
| rs76477273 | chr2:61832252:A:C | - | 0.202813789949997 | 0.0137927686637354 | GBM | Female-baised eQTL |
| rs7569467 | chr2:61852132:T:G | - | 0.194738032823588 | 0.045312124575671 | GBM | Female-baised eQTL |
| rs6715556 | chr2:61854986:C:G | - | 0.194738032823588 | 0.045312124575671 | GBM | Female-baised eQTL |
| rs78036384 | chr2:61859883:C:T | - | 0.194738032823588 | 0.045312124575671 | GBM | Female-baised eQTL |
| rs77986008 | chr2:61861930:C:T | - | 0.194738032823588 | 0.045312124575671 | GBM | Female-baised eQTL |
| rs76248080 | chr2:61873245:G:T | - | 0.194738032823588 | 0.045312124575671 | GBM | Female-baised eQTL |
| rs17514211 | chr2:61881258:C:A | - | 0.194738032823588 | 0.045312124575671 | GBM | Female-baised eQTL |
| rs151311929 | chr2:61882143:G:C | - | 0.194738032823588 | 0.045312124575671 | GBM | Female-baised eQTL |
| rs41281525 | chr2:61888641:G:A | - | 0.194738032823588 | 0.045312124575671 | GBM | Female-baised eQTL |
| rs6721993 | chr2:56963522:C:T | - | 0.119715979506442 | 0.0367617890245812 | LUSC | Female-baised eQTL |
| rs6722435 | chr2:56963703:G:A | - | 0.119715979506442 | 0.0367617890245812 | LUSC | Female-baised eQTL |
| rs7600910 | chr2:59849134:A:T | - | 0.0539589376062558 | 0.00397394971158144 | LUAD | Female-baised eQTL |
| rs6751340 | chr2:53960480:A:G | - | 0.0593048164355126 | 0.00784974502785558 | LUAD | Female-baised eQTL |
| rs1362468 | chr2:65669269:G:A | - | 0.050156241876344 | 0.0286391265912485 | LUAD | Female-baised eQTL |
| rs2072469 | chr2:59858805:C:T | - | 0.0478858006871582 | 0.0304624719197225 | LUAD | Female-baised eQTL |
| rs67297386 | chr2:59859150:A:G | - | 0.0478858006871582 | 0.0304624719197225 | LUAD | Female-baised eQTL |
| rs17050470 | chr2:59859260:G:C | - | 0.0478858006871582 | 0.0304624719197225 | LUAD | Female-baised eQTL |
| rs7556914 | chr2:59846412:A:G | - | 0.0456906702107474 | 0.0328076318054991 | LUAD | Female-baised eQTL |
| rs2072470 | chr2:59858275:A:G | - | 0.0452676863169537 | 0.0437287321741989 | LUAD | Female-baised eQTL |
| rs6706213 | chr2:59862013:A:C | - | 0.0452676863169537 | 0.0437287321741989 | LUAD | Female-baised eQTL |
| Female-specific eQTL regulation. |
| SNP ID | SNP Info | Position to Gene | Effect Score | FDR | Cancer Type | Biased Type |
| rs4318420 | chr2:69035988:C:T | - | 0.0510190429429927 | 0.00241573027900106 | HNSC | Male-baised eQTL |
| rs6723508 | chr2:54828491:G:A | - | 0.0414956836382176 | 0.0143655377528863 | HNSC | Male-baised eQTL |
| rs76263432 | chr2:54791201:G:A | - | 0.0480662097384181 | 0.0225375587592036 | HNSC | Male-baised eQTL |
| rs78871734 | chr2:54793078:G:A | - | 0.0480662097384181 | 0.0225375587592036 | HNSC | Male-baised eQTL |
| rs10177161 | chr2:65868766:G:A | - | 0.0490178215784249 | 0.0358627742472397 | HNSC | Male-baised eQTL |
| Opposite sex-biased eQTL regulation. |
| SNP ID | SNP Info | Position to Gene | Male Effect | Male FDR | Female Effect | Female FDR | Sex-biased Gene in Cancer | Cancer Type |
Top |
Sex-biased eQTM regulation of gene |
| Sex-biased eQTM regulation of gene (The figures only show the pairs with FDR<1e-5. For more information please check the below table). |
| eQTM | Description |
 | Gene ID: ENSG00000115507 |
| CpG Site: cg10640333 | |
| Position to Gene: gene,exon,enhancer | |
| Male Effect: -0.313364501538139 | |
| Female Effect: - | |
 | Gene ID: ENSG00000115507 |
| CpG Site: cg10271192 | |
| Position to Gene: gene,enhancer | |
| Male Effect: -0.400512978017673 | |
| Female Effect: - |
| Male-specific eQTM regulation. |
| CpG Site | CpG Postion | Position to Gene | Effect Score | FDR | Cor.r | Cor.Pvalue | Cancer Type |
| cg10640333 | chr2:63053490 | gene,exon,enhancer | -0.313364501538139 | 1.99171878329812e-10 | -0.47273076583189344 | 8.13447438490619e-14 | LUAD |
| cg10271192 | chr2:63052510 | gene,enhancer | -0.400512978017673 | 2.44398401564709e-09 | -0.40920870080664185 | 1.4431485814466034e-12 | LUSC |
| Female-specific eQTM regulation. |
| CpG Site | CpG Postion | Position to Gene | Effect Score | FDR | Cor.r | Cor.Pvalue | Cancer Type |
| Opposite sex-biased eQTM regulation. |
| CpG Site | CpG Postion | CpG Island | Position to Gene | Male Effect | Male FDR | Female Effect | Female FDR | Male Cor | Male P-value | Female Cor | Female P-value | Sex-biased Coding Gene | Cancer Type |
Top |
Sex-biased sQTL regulation of gene |
| Sex-biased sQTL regulation of gene (The figures only show the pairs with FDR <1e-5. For more information please check the below table). |
| sQTL | Description |
| Male-specific sQTL regulation. |
| ES ID | Skipped Exon | ORF Anno | SNP ID | SNP Info | SNP Position to ES | Effect Score | FDR | Cancer Type | Biased Type |
| Female-specific sQTL regulation. |
| ES ID | Skipped Exon | ORF Anno | SNP ID | SNP Info | SNP Position to ES | Effect Score | FDR | Cancer Type | Biased Type |
| Opposite sex-biased sQTL regulation. |
| ES ID | Skipped Exon | ORF Anno | SNP ID | SNP Info | SNP Position to ES | Male Effect | Male FDR | Female Effect | Female FDR | Cancer Type |
Top |
Sex-biased sQTM regulation of gene |
| Sex-biased sQTM regulation of gene (The figures only show the pairs with FDR <1e-5. For more information please check the below table). |
| sQTM | Description |
| Male-specific sQTM regulation. |
| EX ID | Skipped Exon | CPG Site | CPG Position | Position to EX Events | Effect Score | FDR | Cor.r | Cor.Pvalue | ORF_anno | Cancer Type |
| Female-specific sQTM regulation. |
| EX ID | Skipped Exon | CPG Site | CPG Position | Position to EX Events | Effect Score | FDR | Cor.r | Cor.Pvalue | ORF_anno | Cancer Type |
| Opposite sex-biased sQTM regulation. |
| EX ID | EX Info | Skipped Exon | CPG Site | CPG Position | CPG Island | Position to EX Events | Male Effect | Male FDR | Female Effect | Female FDR | Male Correlation | Male P-value | Female Correlation | Female P-value | ORF_anno | Cancer Type |
Top |
Related disease information of OTX1 |
| Diseases associated with this gene (DisGeNET). |
| Gene ID | Gene Symbol | Disease ID | Disease Name | Number of PMID | Source |
